Register Now - Beyond Recruitment: The Future of Patient Site Engagement in Oncology Clinical Trials
Commentary|Videos|November 27, 2024

Solving Clinical Technology Challenges with Integration

In this video interview, Jeff Sidell, PhD, chief technology officer, Advarra, highlights how integration can simplify processes.

In a recent video interview with Applied Clinical Trials, Jeff Sidell, PhD, chief technology officer, Advarra, discussed current challenges in clinical research technology. He highlighted the overabundance of systems and emphasized the need for integration to streamline processes and reduce administrative overhead. Sidell also discussed the potential of AI, particularly predictive analytics, to automate repetitive tasks, enhancing efficiency and quality.

A transcript of Sidell’s conversation with ACT can be found below.

ACT: How can stakeholders address some of the technology overload industry is currently experiencing?

Sidell: One simple answer is integration. I've been in technology for long enough that I've seen when there's an integration play, so we're going integrate all these systems together, and you'll only have to log on once, and you only have to enter data once, and it's a good idea, but there's always a struggle, whose integration are you going to use? It's sort of like, who's going to be the first among equals? I still think it's possible. I think that, Advarra, for example, is in a good position to because we start at the very beginning of a clinical trial, when a protocol document is submitted to the IRB (institutional review board), all the way through to the conduct of the trial at the sites. Just like everybody else, we're going to make a play to be the integration provider. I think we're a little farther along than some of the other solution providers, but it's going to be a horse race.


Related to this article

Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Closing the Community Access Gap: Q&A with Kent Thoelke, Paradigm Health
In this Q&A, Kent Thoelke, CEO of Paradigm Health, discusses why participation gaps in community and rural settings come down to both patient cost barriers and site infrastructure, how legacy workflows weigh on community clinics, and what policy and technology changes it would take to make clinical research a real care option for more patients.
© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.